However, the use of DGAT inhibitors might also improve the efficacy of anti-cancer drugs for the treatment of patients with a high risk of metastases associated to low levels of Elovl5 by suppressing the resistance or buffering of these anti-cancer drugs by LD [47–49]. This evidence concerns the gene ELOVL5 and cancer.